BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23623832)

  • 21. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
    Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R
    Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay.
    Bristow RE; Smith A; Zhang Z; Chan DW; Crutcher G; Fung ET; Munroe DG
    Gynecol Oncol; 2013 Feb; 128(2):252-9. PubMed ID: 23178277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
    Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis.
    Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K
    Gynecol Oncol; 2005 Feb; 96(2):516-9. PubMed ID: 15661245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
    Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival.
    Zhou F; Tao G; Chen X; Xie W; Liu M; Cao X
    Clin Chem Lab Med; 2014 May; 52(5):735-42. PubMed ID: 24327526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection.
    Erkanli A; Taylor DD; Dean D; Eksir F; Egger D; Geyer J; Nelson BH; Stone B; Fritsche HA; Roden RB
    Cancer Res; 2006 Feb; 66(3):1792-8. PubMed ID: 16452240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors.
    Zachariah RR; Schmid S; Buerki N; Radpour R; Holzgreve W; Zhong X
    Obstet Gynecol; 2008 Oct; 112(4):843-50. PubMed ID: 18827127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of OPCML methylation, a possible epigenetic marker, from free serum circulating DNA to improve the diagnosis of early-stage ovarian epithelial cancer.
    Wang B; Yu L; Luo X; Huang L; Li QS; Shao XS; Liu Y; Fan Y; Yang GZ
    Oncol Lett; 2017 Jul; 14(1):217-223. PubMed ID: 28693156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
    Baron AT; Cora EM; Lafky JM; Boardman CH; Buenafe MC; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of serum CA-125 levels in early-stage epithelial ovarian cancer on preoperative CT and MRI.
    Kim HS; Kim JW; Cho JY; Chung HH; Park NH; Song YS; Kim SH; Kang SB
    Eur J Surg Oncol; 2009 Aug; 35(8):870-6. PubMed ID: 19179039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma.
    Ho CM; Lai HC; Huang SH; Chien TY; Lin MC; Chang SF
    Eur J Clin Invest; 2010 Apr; 40(4):310-8. PubMed ID: 20486992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
    Camlica H; Duranyildiz D; Tas F; Yasasever V
    Am J Clin Oncol; 2008 Dec; 31(6):585-8. PubMed ID: 19060592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer.
    Singh A; Gupta S; Badarukhiya JA; Sachan M
    Int J Cancer; 2020 Sep; 147(6):1740-1752. PubMed ID: 32191343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker.
    Nishio M; Sakakura C; Nagata T; Komiyama S; Miyashita A; Hamada T; Kuryu Y; Ikoma H; Kubota T; Kimura A; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Kokuba Y; Sonoyama T; Ida H; Ito K; Chiba T; Ito Y; Otsuji E
    Anticancer Res; 2010 Jul; 30(7):2673-82. PubMed ID: 20682997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of RASSF1A promoter hypermethylation in serum DNA of non-small cell lung cancer].
    Yu ZH; Wang YC; Chen LB; Song Y; Liu C; Xia XY; Lin Q; Ma CY
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):284-7. PubMed ID: 18788633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of methylated tissue factor pathway inhibitor 2 and human long DNA in fecal samples of patients with colorectal cancer in China.
    Zhang J; Yang S; Xie Y; Chen X; Zhao Y; He D; Li J
    Cancer Epidemiol; 2012 Feb; 36(1):73-7. PubMed ID: 21621497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer.
    Bearzatto A; Conte D; Frattini M; Zaffaroni N; Andriani F; Balestra D; Tavecchio L; Daidone MG; Sozzi G
    Clin Cancer Res; 2002 Dec; 8(12):3782-7. PubMed ID: 12473590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
    Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
    Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.